Breaking Finance News

Pfizer (NYSE:PFE) has been downgraded from Buy to Hold in a statement by Jefferies earlier today.

Boasting a price of $33.07, Pfizer (NYSE:PFE) traded -1.04% lower on the day. With the last stock price close down -4.48% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Pfizer has recorded a 50-day average of $34.14 and a two hundred day average of $34.26. Volume of trade was down over the average, with 2,474,112 shares of PFE changing hands under the typical 18,868,500

Jefferies has downgraded Pfizer (NYSE:PFE) from Buy to Hold in a statement released on 10/13/2016.

On 5/12/2016, Berenberg Bank released a statement for Pfizer (NYSE:PFE) bumped up the target price from $0.00 to $38.00 that suggested an upside of 0.15%.

Performance Chart

Pfizer (NYSE:PFE)

With a total market value of $0, Pfizer has price-earnings ratio of 29.01 with a one year low of $28.25 and a one year high of $37.39 .

A total of 20 equity analysts have released a ratings update on PFE. Four equity analysts rating the company a strong buy, ten equity analysts rating the company a buy, seven equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $38.58.

Brief Synopsis About Pfizer (NYSE:PFE)

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha. The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira's One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. The Company's subsidiaries include Hospira, Inc. and Medivation, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *